Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

Estey E, Karp JE, Emadi A, Othus M, Gale RP.

Leukemia. 2020 Mar;34(3):671-681. doi: 10.1038/s41375-019-0704-5. Epub 2020 Jan 8. Review.

PMID:
31915366
2.

Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.

Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I.

Leukemia. 2020 Jan 3. doi: 10.1038/s41375-019-0693-4. [Epub ahead of print]

PMID:
31900407
3.

Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J, Rudek MA, Beumer JH; ETCTN-6745 study team.

Cancer Chemother Pharmacol. 2019 Feb;83(2):319-328. doi: 10.1007/s00280-018-3731-4. Epub 2018 Nov 20.

4.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, Mukhopadhyay R, Vanura K, Blazar BR, Karp JE, Luznik L, Gojo I.

JCI Insight. 2018 Nov 2;3(21). pii: 120974. doi: 10.1172/jci.insight.120974.

5.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

6.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
7.

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20.

8.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

9.

Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.

Mehrotra S, Gopalakrishnan M, Gobburu J, Ji J, Greer JM, Piekarz R, Karp JE, Pratz KW, Rudek MA.

Clin Cancer Res. 2017 Nov 1;23(21):6421-6429. doi: 10.1158/1078-0432.CCR-17-0143. Epub 2017 Jul 27.

10.
11.

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.

Knorr KL, Finn LE, Smith BD, Hess AD, Foran JM, Karp JE, Kaufmann SH.

Stem Cells Transl Med. 2017 Mar;6(3):840-850. doi: 10.5966/sctm.2016-0034. Epub 2016 Nov 7.

12.

Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.

LaCerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA.

Clin Cancer Res. 2017 Jul 15;23(14):3592-3600. doi: 10.1158/1078-0432.CCR-16-2629. Epub 2017 Feb 7.

13.

Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.

Mehrotra S, Gopalakrishnan M, Gobburu J, Greer JM, Piekarz R, Karp JE, Pratz K, Rudek MA.

Br J Clin Pharmacol. 2017 Aug;83(8):1688-1700. doi: 10.1111/bcp.13253. Epub 2017 Mar 19.

14.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

15.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

16.

When the Minimal Becomes Measurable.

Hourigan CS, Goswami M, Battiwalla M, Barrett AJ, Sheela S, Karp JE, Lai C.

J Clin Oncol. 2016 Jul 20;34(21):2557-8. doi: 10.1200/JCO.2016.67.6395. Epub 2016 May 16. No abstract available.

PMID:
27185839
17.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH.

Clin Cancer Res. 2016 Aug 1;22(15):3894-902. doi: 10.1158/1078-0432.CCR-15-2351. Epub 2016 Mar 15.

18.

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH.

Blood. 2016 Jun 2;127(22):2711-22. doi: 10.1182/blood-2015-02-629485. Epub 2016 Feb 25.

19.

Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

Karp JE, Wolff AC.

Cancer. 2016 Jan 15;122(2):178-80. doi: 10.1002/cncr.29613. Epub 2015 Dec 7. No abstract available.

20.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P.

J Natl Cancer Inst. 2015 Nov 9;108(3). doi: 10.1093/jnci/djv335. Print 2016 Mar.

21.

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

Zeidner JF, Karp JE.

Leuk Res. 2015 Dec;39(12):1312-8. doi: 10.1016/j.leukres.2015.10.010. Epub 2015 Oct 19. Review.

PMID:
26521988
22.

Precision medicine for acute myeloid leukemia.

Lai C, Karp JE, Hourigan CS.

Expert Rev Hematol. 2016 Jan;9(1):1-3. doi: 10.1586/17474086.2016.1107471. Epub 2015 Oct 30.

23.

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.

Dai H, Ding H, Meng XW, Peterson KL, Schneider PA, Karp JE, Kaufmann SH.

Genes Dev. 2015 Oct 15;29(20):2140-52. doi: 10.1101/gad.267997.115.

24.

Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts.

Kremer KN, Dudakovic A, Hess AD, Smith BD, Karp JE, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE.

J Biol Chem. 2015 Dec 4;290(49):29478-92. doi: 10.1074/jbc.M115.668160. Epub 2015 Oct 21.

25.

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, Karp JE, Kaufmann SH.

Cell Death Differ. 2015 Dec;22(12):2133-42. doi: 10.1038/cdd.2015.74. Epub 2015 Jun 5.

26.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

27.

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.

Ramos NR, Mo CC, Karp JE, Hourigan CS.

J Clin Med. 2015 Apr;4(4):665-95. doi: 10.3390/jcm4040665.

28.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE.

J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22. Erratum in: J Clin Oncol. 2015 Apr 1;33(10):1227.

29.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

30.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica. 2015 Feb;100(2):231-7. doi: 10.3324/haematol.2014.114769. Epub 2014 Nov 7.

31.

New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.

Gojo I, Karp JE.

Clin Cancer Res. 2014 Dec 15;20(24):6233-41. doi: 10.1158/1078-0432.CCR-14-0900. Epub 2014 Oct 16. Review.

32.

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A.

Am J Hematol. 2014 Sep;89(9):936-8. doi: 10.1002/ajh.23782. Epub 2014 Jun 23. No abstract available.

33.

Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.

Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH.

J Biol Chem. 2014 Jul 25;289(30):20543-58.

34.

Reason for CPXcitement in AML.

Zeidner JF, Karp JE.

Blood. 2014 May 22;123(21):3211-2. doi: 10.1182/blood-2014-04-568725. No abstract available.

PMID:
24855187
35.

Osteoblasts protect AML cells from SDF-1-induced apoptosis.

Kremer KN, Dudakovic A, McGee-Lawrence ME, Philips RL, Hess AD, Smith BD, van Wijnen AJ, Karp JE, Kaufmann SH, Westendorf JJ, Hedin KE.

J Cell Biochem. 2014 Jun;115(6):1128-37.

36.

Epidemiology of Candida kefyr in patients with hematologic malignancies.

Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, Zhang SX, Lavallée C, Perl TM, Neofytos D.

J Clin Microbiol. 2014 Jun;52(6):1830-7. doi: 10.1128/JCM.00131-14. Epub 2014 Mar 12.

37.

The state of the union on treatment of acute myeloid leukemia.

Emadi A, Karp JE.

Leuk Lymphoma. 2014 Nov;55(11):2423-5. doi: 10.3109/10428194.2014.897705. Epub 2014 Mar 25. No abstract available.

PMID:
24576164
38.

Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Dilley RL, Poh W, Gladstone DE, Herman JG, Showel MM, Karp JE, McDevitt MA, Pratz KW.

Leuk Res. 2014 Mar;38(3):411-7. doi: 10.1016/j.leukres.2013.12.019. Epub 2013 Dec 30.

39.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

40.

Personalized therapy for acute myeloid leukemia.

Hourigan CS, Karp JE.

Cancer Discov. 2013 Dec;3(12):1336-8. doi: 10.1158/2159-8290.CD-13-0832.

41.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R.

Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31.

42.

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH.

Haematologica. 2014 Jan;99(1):60-9. doi: 10.3324/haematol.2013.087734. Epub 2013 Aug 30.

43.

Minimal residual disease in acute myeloid leukaemia.

Hourigan CS, Karp JE.

Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25. Review.

44.

CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.

Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, Smith BD, Rodriguez-Ramirez C, Karp JE, Kaufmann SH, Hedin KE.

J Biol Chem. 2013 Aug 9;288(32):22899-914. doi: 10.1074/jbc.M113.449926. Epub 2013 Jun 24.

45.

Lessons from tumor reversion for cancer treatment.

Amson R, Karp JE, Telerman A.

Curr Opin Oncol. 2013 Jan;25(1):59-65. doi: 10.1097/CCO.0b013e32835b7d21. Review.

PMID:
23165143
46.

Prevention and treatment of cancer-related infections.

Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45.

PMID:
23138169
47.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH.

Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

48.

CD30 in myeloid malignancies: hitting the bull's-eye with an available dart.

Emadi A, Karp JE.

Leuk Lymphoma. 2013 Apr;54(4):679-80. doi: 10.3109/10428194.2012.728703. Epub 2012 Sep 28. No abstract available.

PMID:
22966972
49.

Athletic cervical spine injury in the setting of fusion failure of the anterior and posterior atlas.

Petre BM, Karp JE, Riley LH 3rd.

Orthopedics. 2012 Sep;35(9):e1449-52. doi: 10.3928/01477447-20120822-39.

PMID:
22955419
50.

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.

Emadi A, Karp JE.

Pharmacogenomics. 2012 Aug;13(11):1257-69. doi: 10.2217/pgs.12.102. Review.

Supplemental Content

Support Center